Auto-Immune Drug Focus - Track Autoimmune Developments Worldwide

DUBLIN, Sept. 24, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/5xz4lp/autoimmune_drug) has announced the addition of the "AutoImmune Drug Focus Issue" newsletter to their offering.

This first approved generic glatiramer acetate has been a long time coming, but the hesitancy in launching shows that the battle to produce a generic Copaxone is not yet over. FDA approval will nonetheless give Sandoz (Novartis) and Momenta Pharmaceuticals grounds to urge the courts to expedite their decision over Copaxone's patents; a launch can be expected immediately upon settlement of this consideration.

A business publication for tracking autoimmune developments worldwide

Do you want to keep up to date with all the latest developments in this important and high-value pharmaceutical area? Autoimmune Drug Focus (ADF) provides a simple, time-saving way to do just that. It summarises all the latest developments in an easy-to-read format, providing company and compound indexes. Can you afford to be without it?

With approximately 4% of the population suffering from an autoimmune disease and with the prevalence of these disorders rising, it is unsurprising that each year, millions of dollars are devoted to researching the causes of autoimmune disorders.

Regular sections in ADF include:

- Type 1 Diabetes
- Inflammatory Bowel Diseases (with features on Crohn's disease and ulcerative colitis)
- Multiple Sclerosis
- Musculoskeletal Disorders (with features on rheumatoid arthritis, and more)
- Psoriasis
- General Developments

Key Topics Covered:

1. First Generic Copaxone Approved But Launch Remains Uncertain Diabetes

2. Agreements

3. AstraZeneca/HSCI Enter Research Collaboration For Diabetes

4. RGI Enters Type I Diabetes Collaboration With JDRF And Pfizer

5.Product Updates
- FDA Accepts Tresiba/Ryzodeg Resubmissions For Review
- Semma Raises Funds To Develop Type I Diabetes Cell Therapy; Signs Deal With Novartis
- Novo Nordisk To Resubmit Tresiba/Ryzodeg NDAs To FDA
- Biocon Gains Mexico Insulin Glargine Approval
- Afrezza Aggressive Pricing Strategy View Playing Out

6. Novo Nordisk Opens Insulin Manufacturing Facility In Russia
- R&D
- Faster-Acting Insulin Aspart Achieves HbA1c Reduction Over NovoRapid In Phase IIIa Trials

7. Oramed Enrols First Patient In Glucose Clamp Study For Oral Insulin Inflammatory Bowel Diseases

8. Agreements
- Low-Risk Investment For Celgene To Translate Into Positive Gains For Small Stem Cell Biotech
- Product Updates
- Qu Biologics Granted US Patent Covering E. Coli Components To Treat CD
- Certain Shire Lialda And Gattex Patents Challenged By Hayman

9. TiGenix Granted US Patent Covering Adipose-Derived Stem Cells For Fistula
- Calprotectin IBDoc Home Test Kit Launched In Europe
- R&D
- Successful Development Of SGX203 Will Corner The Paediatric CD Market

10. Multiple Sclerosis

11. Product Updates
- EMA Validates Zinbryta MAA For MS
- US PTO Declares Interference Between Forward Pharma And Biogen
- Forward Pharma Receives Decision To Grant From EPO For DMF Patent In Europe

12. FDA Accepts Filing Of Betaconnect For RRMS Patients Taking Betaseron
- R&D
- First Patient Enrolled In Laquinimod Phase II Study For PPMS
- Receptos Completes Enrolment In RADIANCE Phase III Trial Of Ozanimod In RMS Musculoskeletal Disorders

13. Arthritis - Agreements
- Coherus And Baxter Amend Etanercept Biosimilar Collaboration
- Product Updates
- EMA Validates Biogen's Infliximab For Review
- Hospira's Infliximab Launched In Canada
- R&D
- Ablynx Initiates Second Phase IIb Of ALX-0061 In RA Psoriasis

14. Agreements
- Janssen Initiates Guselkumab PsA Trial, Triggering Milestone To MorphoSys
- Product Updates
- Humira Gains EU Approval For Plaque Psoriasis In Children
- Dr Reddy's/Promius File Three NDAs With FDA
- R&D
- Can-Fite's CF-101 Phase II/III Psoriasis Trial Misses Primary Endpoint

15. Ixekizumab Trials Are Progressing Well But A Competitive Market Looms - General Developments

16. Agreements
- Intarcia/Numab Collaborate To Develop Therapies In Multiple Indications
- BMS Licenses Autoimmune Research Programme From Novo Nordisk
- Product Updates
- CFDA Accepts IND For WuXi MedImmune's Anti-IL-6 Monoclonal Antibody

17. R&D
- EMA Lupus Guideline Will Encourage New Treatments

18. Behçet's Disease Approval For Otezla Would Boost Celgene's Developing Autoimmune Presence - Corporate Activity

19. Diamyd Medical Receives SEK15mn In Direct Issue
- Valeant Completes Salix Acquisition

20. Novo Nordisk Extends Paediatric Diabetes Programme In Developing Countries
- H216 Will Be Key For High Risk/High Reward Opexa

21. Antares Settles Lawsuits With Medac
- Biogen Will Continue To Gain Share Of MS Market

22. Esbriet Sales Will Reach Blockbuster Status In 2016
- Conference Listings

For more information visit http://www.researchandmarkets.com/research/5xz4lp/autoimmune_drug

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets